Syros Pharmaceuticals Inc.

NAS: SYRS

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Syros Pharmaceuticals Inc.

After Hours

--Quotes are delayed by 20 min

Sep 21, 2023, 6:04 p.m.

SYRS

/zigman2/quotes/201168308/composite

3.77

Change

-0.18 -4.56%

Volume

Volume 330

Quotes are delayed by 20 min

/zigman2/quotes/201168308/composite

Previous close

$ 3.92

$ 3.95

Change

+0.03 +0.77%

Day low

Day high

$3.82

$3.96

52 week low

52 week high

$2.42

$6.95

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Syros Pharmaceuticals Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	2.05M	1.98M	15.09M	23.49M	14.88M
Sales Growth	-	-3.32%	661.50%	55.62%	-36.65%
Cost of Goods Sold (COGS) incl. D&A	-	-	-	-	2.97M
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	1.6M	2.72M	3.04M	3.02M	2.97M
Depreciation	1.6M	2.72M	3.04M	3.02M	2.97M
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	-	-	-	-
Gross Income	-	-	-	-	11.91M
Gross Income Growth	-	-	-	-	-
Gross Profit Margin	-	-	-	-	80.06%	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	64.74M	77M	94.36M	119.89M	138.28M
Research & Development	50.18M	58.25M	76.07M	97.11M	109.24M
Other SG&A	14.56M	18.76M	18.29M	22.78M	29.04M
SGA Growth	-	18.94%	22.54%	27.06%	15.34%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	375,000	(16.68M)	(33.71M)
EBIT after Unusual Expense	-	-	(82.67M)	(82.74M)	(92.65M)
Non Operating Income/Expense	2.02M	2.3M	-	-	-
Non-Operating Interest Income	-	-	426,000	87,000	2.13M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	-	1.79M	3.91M	4.13M
Interest Expense Growth	-	-	-	118.02%	5.81%
Gross Interest Expense	-	-	1.79M	3.91M	4.13M
Interest Capitalized	-	-	-	-	-
Pretax Income	(62.28M)	(75.44M)	(84.04M)	(86.56M)	(94.65M)
Pretax Income Growth	-	-21.13%	-11.40%	-3.00%	-9.35%
Pretax Margin	-	-	-	-	-636.12%	NA
Income Tax	-	-	-	-	-
Income Tax - Current Domestic	-	-	-	-	-
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	-	-	-	-	-
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(62.28M)	(75.44M)	(84.04M)	(86.56M)	(94.65M)
Minority Interest Expense	-	-	-	-	-
Net Income	(62.28M)	(75.44M)	(84.04M)	(86.56M)	(94.65M)
Net Income Growth	-	-21.13%	-11.40%	-3.00%	-9.35%
Net Margin Growth	-	-	-	-	-636.12%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(62.28M)	(75.44M)	(84.04M)	(86.56M)	(94.65M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(62.28M)	(75.44M)	(84.04M)	(86.56M)	(94.65M)
EPS (Basic)	(19.07)	(18.76)	(18.25)	(13.84)	(7.49)
EPS (Basic) Growth	-	1.66%	2.70%	24.15%	45.86%
Basic Shares Outstanding	3.27M	4.02M	4.61M	6.25M	12.63M
EPS (Diluted)	(19.07)	(18.76)	(18.25)	(13.84)	(7.49)
EPS (Diluted) Growth	-	1.66%	2.70%	24.15%	45.86%
Diluted Shares Outstanding	3.27M	4.02M	4.61M	6.25M	12.63M
EBITDA	(62.69M)	(75.02M)	(79.26M)	(96.4M)	(123.4M)
EBITDA Growth	-	-19.66%	-5.66%	-21.62%	-28.00%
EBITDA Margin	-	-	-	-	-829.27%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Syros Pharmaceuticals Inc.

Annual Financials for Syros Pharmaceuticals Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk